December 2024 in “Journal of the European Academy of Dermatology and Venereology” Bimatoprost shows promise for treating vitiligo, especially when combined with other therapies.
6 citations
,
May 1986 in “Cancer Chemotherapy and Pharmacology” The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.
153 citations
,
January 2001 in “Science” Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.
74 citations
,
February 2018 in “Journal of the American Academy of Dermatology”
Flubendazole in a nanoemulsion can potentially treat lung cancer and cryptococcal meningitis effectively and safely.
1 citations
,
January 2025 in “Frontiers in Oncology” REV7 is crucial for genome stability and cancer treatment, making it a potential target for therapy.
September 2023 in “Journal of the American Academy of Dermatology” BAP1 mutations are rare in pediatric melanocytic tumors and may develop later in life.
7 citations
,
May 2008 in “Journal of Veterinary Internal Medicine” A cat had a rare severe reaction to fenbendazole, but recovered with treatment.
1 citations
,
June 2007 in “Journal of Clinical Oncology” Weekly bicalutamide is safe and effective, with 50 mg/week recommended.
October 2018 in “Annals of oncology” Topical calcitriol (BPM31543) is safe for preventing hair loss from chemotherapy and shows some effectiveness.
19 citations
,
October 2016 in “Journal of oncology pharmacy practice” A cancer patient's hair became permanently curly after treatment with nivolumab.
73 citations
,
October 2001 in “Epilepsia” Children taking higher doses of valproic acid had lower biotinidase activity, which may lead to biotin deficiency, but biotin supplements could help.
8 citations
,
October 2019 in “Dermatologic Therapy” Bicalutamide improves hair density in women safely.
January 2025 in “Recent Patents on Anti-Cancer Drug Discovery” The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
16 citations
,
March 1986 in “Biochemical Pharmacology”
3 citations
,
September 2020 in “Molecular Brain” The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.
August 2025 in “Fabad Journal of Pharmaceutical Sciences” Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.
November 2001 in “Oncology Times” The committee decided not to approve the drug due to low effectiveness and high risks.
May 2022 in “Annals of Oncology” Photobiomodulation therapy may speed up hair regrowth after chemotherapy in the short term.
February 2025 in “FASEB BioAdvances” Verteporfin reduces growth and stem cell traits in rat hair follicle cells by blocking the Hippo pathway.
23 citations
,
February 2019 in “International Journal of Molecular Sciences” Activin B can boost hair growth by promoting cell proliferation and cell cycle progression.
16 citations
,
February 2008 in “PubMed” Vitamin B12 deficiency can cause skin darkening and white hair, but it's reversible.
2 citations
,
January 2022 in “JAAD Case Reports” The rash resolved after stopping ponatinib.
February 2024 in “Indian Journal of Chemistry” Compound N4 effectively kills breast cancer cells and compounds N2 and N3 have strong antibacterial and antifungal properties.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” The study suggests a link between varicella-zoster virus and segmental vitiligo, with evidence of the virus disrupting skin pigment cells.
65 citations
,
October 2015 in “Acta Biomaterialia” The nano-carrier makes etoposide safer and more effective against lung cancer.
68 citations
,
January 2013 in “BMC Pharmacology and Toxicology” Glibenclamide slows breast cancer cell growth by stopping cell division.
4 citations
,
April 2007 in “Journal of Pediatric Gastroenterology and Nutrition” A liver transplant patient with APECED had a rare VZV recurrence and pneumonia, treated successfully, but later died from other infections.
August 2010 in “Oncology Times” Provenge extends prostate cancer survival by about 4 months.
1 citations
,
July 2014 in “International Journal of Dermatology” A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.